NVS Novartis AG

86.96
-0.08  -0%
Previous Close 87.04
Open 87.29
52 Week Low 69.1801
52 Week High 99.8429
Market Cap $199,049,667,060
Shares 2,288,979,612
Float 2,288,979,612
Enterprise Value $226,823,471,722
Volume 2,676,763
Av. Daily Volume 1,805,702
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
BYL719 + fulvestrant
HR + Metastatic breast cancer (MBC)
Approved
Approved
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Inclisiran
Hyperlipidemia
PDUFA
PDUFA
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Asciminib (ABL001)
Chronic myeloid leukemia
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
PDR001
Metastatic melanoma
NDA Filing
NDA Filing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Beovu (Brolucizumab)
Diabetic macular edema (DME)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Canakinumab (ACZ885)
Non-small cell lung cancer (NSCLC)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Lu-PSMA-617
Metastatic castration-resistant prostate cancer (mCRPC)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Entresto - PARADISE-MI
AMI (acute myocardial infarction)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Zolgensma AVXS-101 STR1VE EU
Spinal muscular atrophy (SMA) Type 1
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Entresto - Panorama
Heart failure
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
QGE031 - Pearl 1
Chronic spontaneous urticaria
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Kisqali - MONALEESA-2
Breast cancer
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Zolgensma AVXS-101
Spinal muscular atrophy (SMA) Type 2
BLA Filing
BLA Filing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Zolgensma AVXS-101 SPRINT
Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Entresto - PERSPECTIVE
Heart failure
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3
Phase 3
Phase 3 data met primary endpoint - October 16, 2019.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Approved
Approved
FDA approval announced August 20, 2020.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3
Phase 3
Phase 3 trial met primary and secondary endpoints - July 23, 2020.
CNP520
Alzheimer’s Disease
Phase 2/3
Phase 2/3
Phase 2/3 trial discontinued due to lack of efficacy.
LJN452
Non-alcoholic steatohepatitis (NASH)
Phase 2
Phase 2
Phase 2 trial completed 2Q 2020.
Cosentyx (secukinumab) - SURPASS
Ankylosing spondylitis (AS)
Phase 3
Phase 3
Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.
Cosentyx (secukinumab) - PREVENT
Non-radiographic axial spondyloarthritis
Approved
Approved
FDA Approval announced June 16, 2020.
Capmatinib
Non-small cell lung cancer
Approved
Approved
FDA Approval announced May 6, 2020.
Cosentyx
Psoriatic arthritis
Phase 3
Phase 3
Phase 3 data did not meet primary endpoint - October 31, 2019.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
Approved
Approved
Approved August 29, 2017.
IONSYS
Acute postoperative pain
Approved
Approved
Approved April 30, 2015.
Oritavancin
ABSSSI
Approved
Approved
Approved August 6 2014 under priority review.
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved
Approved
CRL April 30 2014. Approved June 22 2015
QAW039 (fevipiprant) - LUSTER-1
Asthma
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - December 16, 2019.
Crizanlizumab
Sickle cell disease
Approved
Approved
FDA Approval announced November 15, 2019.
Biosimilar pegfilgrastim
Pegfilgrastim biosimilar
Approved
Approved
FDA Approval announced November 5, 2019.
QAW039 (fevipiprant) - ZEAL
Asthma
Phase 3
Phase 3
Phase 3 data did not meet primary endpoint - noted October 22, 2019.
RTH258 (brolucizumab)
Wet age-related macular degeneration (AMD)
Approved
Approved
FDA Approval announced October 8, 2019.
QMF149
Asthma
Phase 3
Phase 3
Phase 3 trial met primary endpoint.
Zolgensma AVXS-101
Spinal muscular atrophy (SMA) Type 1
Approved
Approved
FDA Approval announced May 24, 2019.
Entresto - PARAGON-HF
HF-pEF (heart failure with preserved ejection fraction)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - July 29, 2019.
Mayzent (siponimod/BAF312)
Secondary progressive multiple sclerosis
Approved
Approved
FDA approval announced March 26, 2019.
Egaten
Fascioliasis
Approved
Approved
FDA Approval announced February 13, 2019.
Promacta (eltrombopag)
Severe aplastic anemia (SAA)
Approved
Approved
sNDA approval announced November 16, 2018.
Adalimumab
Rheumatoid Arthritis
Approved
Approved
FDA approval announced October 31, 2018.
ACZ885 (canakinumab)
CV risk reduction
CRL
CRL
CRL announced October 18, 2018.
Erenumab
Migraine
Approved
Approved
Approval announced May 17, 2018.
Fingolimod
Multiple Sclerosis (MS)
Approved
Approved
Approval announced May 11, 2018.
Biosimilar rituximab
Various blood cancers, rheumatoid arthritis.
CRL
CRL
CRL issued May 2, 2018.
Kymriah (CTL019 )- JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Approved
Approved
Approval announced May 1, 2018.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Melanoma with BRAF V600E or V600K mutations
Approved
Approved
Approval announced April 30, 2018.
Cosentyx
Psoriasis
Approved
Approved
FDA approval announced February 8, 2018.
Lutathera
Inoperable progressive midgut NETs
Approved
Approved
Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Approved
Approved
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Kymriah (CTL019)
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Approved
Approved
Approval announced early - August 30, 2017.
LEE011
HR+/HER2- advanced breast cancer
Approved
Approved
Priority review granted November 1, 2016. Approval announced March 13, 2017.
RELAX-AHF-2 (RLX030)
Acute heart failure
Phase 3
Phase 3
Phase 3 data released March 22, 2017 - primary endpoints not met.
Zykadia
First-line use in patients with ALK+ metastatic NSCLC
Approved
Approved
Priority review granted February 22, 2017. Approval announced May 26, 2017.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Approved
Approved
FDA Approval announced June 22, 2017.

Latest News

  1. EAST HANOVER, N.J., Sept. 16, 2020 /PRNewswire/ -- Today the Novartis US Foundation announced a total commitment of USD 25 million to develop partnerships and fund community organizations and programs that address health inequities, with a focus on diversity in clinical trials, in the United States. This commitment reinforces the Novartis US Foundation mission to improve health in underserved communities in the United States by creating innovative and sustainable solutions to expand access to healthcare and build trust within the healthcare system.

    "In the wake of the COVID-19 pandemic and heightened attention on racial injustice in the US, there has been new and significant recognition of disparities in care in minority communities. We have accelerated our commitment to create innovative and sustainable partnerships that have the potential to improve health equity in underserved communities, including African American/Black and Hispanic communities," said Tom Kendris, US Country President, Novartis Corporation, Chairman, Board of Trustees, Novartis US Foundation.

    Since re-focusing its mission last year, the Novartis US Foundation has committed more than USD 10 million to develop partnerships to enable healthcare systems to better meet the needs of their patients by addressing barriers to care, or by identifying changes needed to address the underlying causes of health disparities. This support included signature partnerships with New Jersey Primary Care Association, The CDC Foundation, Institute for Healthcare Improvement and USD 5 million to support COVID-19 response efforts, including 40 grants to support local communities.

    A key area of focus for the additional commitment will be in addressing the vast underrepresentation of minorities, including Black Americans, in clinical trials. In 2019, African Americans/Blacks made up 13.5% of the US population, but only 9% of clinical trial participants1,2. Diversity in clinical trials is critical to understanding how medicines will work in all patient populations impacted by the disease.

    "We believe the Novartis US Foundation can serve as a catalyst for change through a multi-year, multi-million dollar commitment. As part of this effort, we will collaborate with partners and support industry-wide programs to improve diversity in clinical trials through systemic and policy-driven solutions that go beyond calls to study sponsors to be more inclusive," continued Kendris.

    There are several barriers to clinical trial participation reflective of other systemic issues leading to disparities in health such as, mistrust of the healthcare system, a lack of comfort or understanding of health systems, including clinical trial processes, as well as time and resource constraints associated with participation3. The US Foundation is in the exploration phase to identify all dimensions of these issues and to identify new collaborators from the public, private and advocacy sectors. 

    About Social Determinants of Health and Health Disparities

    CDC defines social determinants of health as the conditions – social, economic and physical – in places where people live, learn, work and play that influence health outcomes of people2. These conditions may include safe and affordable housing, access to education, food security, and clean environments2. When health outcomes are better or worse from one population to the next, there is disparity. Health disparities have impacts reaching far beyond those directly affected by limiting advancements in care and resulting in avoidable costs3. For example, the American Public Health Association found racial disparities in health led to an estimated $93 billion in excess medical care costs and $42 billion in lost productivity4.

    About the Novartis US Foundation

    The Novartis US Foundation is a 501(c)(3) charitable foundation established by Novartis to support philanthropic efforts in the United States. The mission of the Novartis US Foundation is to improve health in underserved communities in the United States by creating innovative and sustainable solutions to expand access to healthcare and build trust within the healthcare system. We do this by supporting sustainable programs and partnerships that strengthen health systems, eliminate barriers to quality health services, and enhance local communities.

    About Novartis

    Located in East Hanover, NJ Novartis Pharmaceuticals Corporation – an affiliate of Novartis – is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis employs about 15,000 people in the United States. For more information, please visit https://www.novartis.us.

    Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS.

    For Novartis multimedia content, please visit https://www.novartis.com/news/media-library 

    For questions about the site or required registration, please contact .

    References

    1. US Food and Drug Administration. 2019 Drug Trials Snapshots Summary Report. Available at: https://www.fda.gov/media/135337/download. Accessed August 27, 2020.
    2. US Census Bureau. Quick Facts. Available at: https://www.census.gov/quickfacts/fact/table/US/RHI225219. Accessed August 27, 2020.
    3. Clark, LT, Watkins, L, Pina, IL, et al. Increasing Diversity in Clinical Trials. Current Problems in Cardiology. 2019; 44(5):148-175.
    4. Centers for Disease Control and Prevention. Social Determinants of Health: Know What Affects Health. Available at: https://www.cdc.gov/socialdeterminants/index.htm. Accessed August 20, 2020.
    5. Turner, A. The Business Case for Racial Equity. WK Kellogg Foundation. Available at: http://ww2.wkkf.org/2018/bcfre/BCRE-National-Report.pdf, Accessed February 13, 2020.
    6. American Public Health Association. Health Equity. Available at: https://www.apha.org/topics-and-issues/health-equity. Accessed February 13, 2020.

    # # #

    Novartis Media Relations





    E-mail:











    Eric Althoff

    Head, US Corp & Country External Comms,

    Global Media & Corp Communications

    +1 646 438 4335

    Jamie Bennett

    Director, US Media Relations

    +1 862 217 3976









     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/novartis-us-foundation-commits-25m-to-improve-health-equity-by-reducing-health-disparities-in-the-us-301132564.html

    SOURCE Novartis US Corporate

    View Full Article Hide Full Article
  2. Industry Leader Joins Vasomune's Board of Directors as the Company Transitions to Clinical Development of AV-001 for the Treatment of COVID-19/pathogen-induced ARDS

    Vasomune Therapeutics, Inc., an early stage therapeutic biopharmaceutical company developing a novel first-in-class medicine for the treatment of COVID-19/pathogen-induced ARDS, today announced the appointment of Meenu Chhabra to the Company's Board of Directors. Ms. Chhabra is the President and Chief Executive Officer of Proteostasis Therapeutics, Inc. (NASDAQ:PTI).

    "Ms. Chhabra is an experienced highly regarded leader in the life sciences industry with particular expertise in operations, business development and finance," said Douglas A. Hamilton, President and Chief Executive…

    Industry Leader Joins Vasomune's Board of Directors as the Company Transitions to Clinical Development of AV-001 for the Treatment of COVID-19/pathogen-induced ARDS

    Vasomune Therapeutics, Inc., an early stage therapeutic biopharmaceutical company developing a novel first-in-class medicine for the treatment of COVID-19/pathogen-induced ARDS, today announced the appointment of Meenu Chhabra to the Company's Board of Directors. Ms. Chhabra is the President and Chief Executive Officer of Proteostasis Therapeutics, Inc. (NASDAQ:PTI).

    "Ms. Chhabra is an experienced highly regarded leader in the life sciences industry with particular expertise in operations, business development and finance," said Douglas A. Hamilton, President and Chief Executive Officer, Vasomune. "We are delighted to have Meenu join the Vasomune team as we transition to the clinic with our novel investigational medicine to treat ARDS."

    Ms. Chhabra has been serving as President and Chief Executive Officer and Director of Proteostasis Therapeutics Inc., since May 2014. From August 2007 to May 2014, Ms. Chhabra was President and Chief Executive Officer at Allozyne, Inc., a biopharmaceutical company. From December 2006 to August 2007, she served as Vice President of Business Development and Licensing at the Novartis Pharmaceuticals division of Novartis AG (NYSE:NVS). From July 2003 to November 2006, she served as Chief Business Officer at BioXell SpA, a spin-off from F. Hoffmann-LaRoche Ltd.'s Milan Research Institute (Italy), where she led corporate development and financing activities. Ms. Chhabra has also held management positions with Fresenius Kabi AG, Warner-Lambert Company, LLC, and Bristol-Myers Squibb Company (NYSE:BMY). She obtained her M.B.A. from York University and her B.Sc. from the University of Toronto. Ms. Chhabra is a member of the Biotechnology Industry Organization (BIO) Board and is a member of the Emerging Companies Section.

    "I'm excited to join Vasomune's Board and help build the company during this important transition and contribute to the company's mission of developing innovative medications for critically ill patients with ARDS and COVID-19 pneumonia," stated Ms. Chhabra.

    About AV-001

    AV-001 is an investigational medicine designed to activate the Tie2 receptor and restore normal barrier defense in the vasculature. Following trauma or infection, the body's host vascular response can become unchecked, leading to vascular leak and ultimately organ failure and death. Vasomune is developing AV-001 for the treatment of pathogen-induced moderate-to-severe ARDS. ARDS is a life-threatening condition that can develop after pneumonia, trauma, shock and sepsis, and is also the leading cause of death for patients infected with COVID-19. Prior to the onset of the coronavirus pandemic, the combined annual incidence of ARDS is approximately 370,000 patients per year in the US and EU with an average mortality rate of 40%. At present, there are no effective therapeutics to treat ARDS.

    About Vasomune Therapeutics

    Vasomune Therapeutics is a private early stage biopharmaceutical company developing the next generation of medicines to harness the body's ability to defend against illness by modifying the host vascular response. The company is transitioning in the near term to the clinic with a novel therapeutic approach to ARDS that involves targeting a signaling molecule in the vasculature responsible for regulating barrier defense. Vascular dysfunction is associated with the pathology of several disease states, including COVID-19 pneumonia, acute lung injury, acute kidney injury, hemorrhagic fever, sepsis and diabetic nephropathy. Vasomune's head office and laboratory is located in Toronto, Canada and US offices in San Mateo CA. For more information about the company and its product candidates, please visit www.vasomune.com or email the President and CEO of Vasomune at .

    View Full Article Hide Full Article
  3. Carrols Restaurant Group, Inc. ("Carrols" or the "Company") (NASDAQ:TAST) today announced that it has appointed Markus Hartmann as the Company's Vice President and General Counsel effective February 18, 2020.

    Daniel T. Accordino, Chairman and Chief Executive Officer of Carrols, commented, "Markus is a great addition to the Carrols executive team and we look forward to benefiting from his varied industry experiences and history of effective leadership. We are excited for Markus to be joining us as we strengthen Carrols' foundation of operating two world-class brands with significant scale advantages and execute on growth opportunities across our multiple attractive markets. We look forward to his building on the existing foundation of excellence…

    Carrols Restaurant Group, Inc. ("Carrols" or the "Company") (NASDAQ:TAST) today announced that it has appointed Markus Hartmann as the Company's Vice President and General Counsel effective February 18, 2020.

    Daniel T. Accordino, Chairman and Chief Executive Officer of Carrols, commented, "Markus is a great addition to the Carrols executive team and we look forward to benefiting from his varied industry experiences and history of effective leadership. We are excited for Markus to be joining us as we strengthen Carrols' foundation of operating two world-class brands with significant scale advantages and execute on growth opportunities across our multiple attractive markets. We look forward to his building on the existing foundation of excellence provided by our legal team."

    Accordino concluded, "We would also like to thank Bill Myers for his 19 years at Carrols and for serving as our General Counsel since 2012. Bill will serve in a transitionary role for a period of time after February 18, 2020."

    Mr. Hartmann is a business-oriented legal leader with experience in both public and private companies. He has practiced law in both domestic and international settings. Markus is a driven executive with experience as both a commercial and legal leader, with a distinguished career spanning more than three decades.

    Mr. Hartmann most recently was the Vice President for Technical Compliance at Mercedes-Benz Research & Development North America, Inc. (a Daimler Company) (XETR: DDAIF). During his tenure, he was responsible for establishing the technical compliance function in North America for Daimler's passenger car and vans division. Mr. Hartmann previously served as the North American General Counsel for Sandoz, Inc. (a division of Novartis) (NYSE:NVS), as well as the European and North American General Counsel for Reckitt Benckiser (LSE:RB) while living and working as an expatriate in the Netherlands.

    Earlier in his career, Mr. Hartmann flew CH-46 Helicopters as a Marine pilot during Desert Shield/Storm. After graduating from law school, then Major Hartmann was designated a Judge Advocate in the Marine Corps Reserve and served as the Staff Judge Advocate to the commander of the Combined Joint Task Force – Horn of Africa (Djibouti) in 2005. Mr. Hartmann retired from the Marine Corps Reserve at the rank of Colonel in 2014.

    He holds a JD from Harvard Law School, an MBA from Le Moyne College and a BA from The Colorado College.

    About the Company

    Carrols is one of largest restaurant franchisees in the United States, and currently operates 1,100 restaurants. It is the largest BURGER KING® franchisee in the United States currently operating 1,035 BURGER KING® restaurants and also operating 65 POPEYES® restaurants. It has operated BURGER KING® restaurants since 1976. For more information on Carrols, please visit the company's website at www.carrols.com.

    Forward-Looking Statements

    Except for the historical information contained in this news release, the matters addressed are forward-looking statements. Forward-looking statements, written, oral or otherwise made, represent Carrols' expectation or belief concerning future events. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions, plans or guidance are also forward-looking statements. Such statements reflect management's current views with respect to future events and are subject to risks and uncertainties, both known and unknown. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. Investors are referred to the full discussion of risks and uncertainties as included in Carrols' filings with the Securities and Exchange Commission.

    View Full Article Hide Full Article
    • Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of cardiovascular events1
       
    • The Medicines Company submitted the New Drug Application (NDA) for inclisiran to the FDA in December 2019
       
    • Comprehensive Phase III inclisiran program showed potent and durable reduction of >50% in LDL-C on top of standard of care, with excellent safety profile2,3,4
       
    • Adds potentially soon-to-launch, first-in-class investigational product, leveraging significant synergies with existing global cardiovascular commercial capabilities

    Basel, January 6, 2020 Novartis AG (NYSE…

    • Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of cardiovascular events1
       
    • The Medicines Company submitted the New Drug Application (NDA) for inclisiran to the FDA in December 2019
       
    • Comprehensive Phase III inclisiran program showed potent and durable reduction of >50% in LDL-C on top of standard of care, with excellent safety profile2,3,4
       
    • Adds potentially soon-to-launch, first-in-class investigational product, leveraging significant synergies with existing global cardiovascular commercial capabilities

    Basel, January 6, 2020 Novartis AG (NYSE:NVS) ("Novartis") today announced that it has completed the acquisition of The Medicines Company (the "Company") through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation ("Purchaser"), with and into the Company, with the Company surviving the merger, without a vote of the Company's stockholders in accordance with Section 251(h) of the Delaware General Corporation Law. In the merger, each share of the Company's common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Purchaser, the Company, any other subsidiary of Novartis or any subsidiary of the Company, or shares that are held in the Company's treasury or shares held by any Company stockholder who has properly demanded and perfected appraisal rights under Delaware law) has been converted into the right to receive USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding. As a result of the merger, the Company became an indirect wholly-owned subsidiary of Novartis and the Company's shares have ceased to be traded on the NASDAQ Global Select Market.

    Vas Narasimhan, CEO of Novartis, said: "Acquiring The Medicines Company and inclisiran gives Novartis a unique opportunity to open up a new chapter on the treatment of the world's leading cause of mortality and disability with a vaccine-like approach. It's a significant step forward on our journey to focus the company, to reimagine medicine, and to bend the curve of life."   

    Marie-France Tschudin, CEO, Novartis Pharmaceuticals said: "I'm looking forward to welcoming associates from The Medicines Company to Novartis. There is a real unmet need for patients living with atherosclerotic cardiovascular disease or familial hypercholesterolemia on current standard of care, who are not achieving LDL cholesterol goals and remain at significant risk of cardiovascular events. With a unique twice yearly, subcutaneous dosing regimen which integrates seamlessly with routine HCP visits, inclisiran has the potential to improve adherence and, potentially, patient outcomes for the millions of people living with ASCVD or FH."

    In December 2019, The Medicines Company submitted the New Drug Application (NDA) for inclisiran to the FDA for use in secondary prevention patients with atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH).

    Disclaimer
    This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potentially," "first-in-class," "investigational," "remain," "submitted," "soon-to-launch," "leveraging," "synergies," "opportunity," "step forward," "new chapter," "journey," "reimagine," "bend the curve of life," "potential," "looking forward," "will," "expected," "expectations," "expanding," "growing," "pipeline," or similar terms, or by express or implied discussions regarding potential marketing approvals for inclisiran or the other investigational products described in this press release, or new indications or labeling for Entresto or the other approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Novartis or The Medicines Company's product, inclisiran, will achieve any particular future financial results, or that Novartis will be able to realize any of potential strategic benefits, synergies or opportunities as a result of the acquisition.  Nor can there be any guarantee that inclisiran will be submitted or approved for sale in any market, or at any particular time.  Neither can there be any guarantee that such product will be successfully commercialized even if regulatory approvals are obtained. Nor can there be any guarantee that Entresto will be commercially successful in the future.  In particular, our expectations could be affected by, among other things:  regulatory actions or delays or government regulation generally, as well as potential regulatory actions or delays with respect to the development of inclisiran; the potential that the strategic benefits, synergies or opportunities expected from the acquisition may not be realized or may take longer to realize than expected; the successful integration of The Medicines Company into the Novartis Group subsequent to the closing of the transaction and the timing of such integration; potential adverse reactions to the transaction by customers, suppliers or strategic partners; dependence on key personnel of The Medicines Company; dependence on third parties to fulfill manufacturing and supply obligations; the uncertainties inherent in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection; safety, quality, data integrity or manufacturing issues; global trends toward health care cost containment, including government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the particular prescribing preferences of physicians and patients; uncertainties regarding actual or potential legal proceedings, including, among others, potential legal proceedings with respect to the acquisition; and other risks and factors referred to in Novartis' current Form 20-F on file with United States Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    About Novartis in Cardiovascular-Renal-Metabolism
    Bending the curve of life requires addressing some of society's biggest public health concerns. Novartis has an established and expanding presence in diseases covering the heart, kidney and metabolic system. In addition to essential treatment Entresto® (sacubitril/valsartan), Novartis has a growing pipeline of potentially first-in-class molecules addressing cardiovascular, metabolic and renal diseases.

    About Novartis
    Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at
    www.novartis.com.

    Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartisnews
    For Novartis multimedia content, please visit www.novartis.com/news/media-library
    For questions about the site or required registration, please contact  
      
    References
    1.   Novartis. Data on file
    2.   Raal FJ et al. Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia. Data presented at: AHA Scientific Sessions 2019, Nov 16-18; Philadelphia, USA.
    3.   Wright RS et al. Inclisiran for subjects with ASCVD and elevated low-density lipoprotein cholesterol. Data presented at: AHA Scientific Sessions 2019, Nov 16-18; Philadelphia, USA
    4.   Ray K et al. Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent. Data presented at: European Society of Cardiology Congress, Aug 29 – Sept 2; Paris, France

    # # #

    Novartis Media Relations
    E-mail:

    Anja von Treskow
    Novartis External Communications
    +41 61 324 2279 (direct)
    +41 79 392 8697 (mobile)
     

     

    Eric Althoff
    Novartis US Communications
    +1 646 438 4335 (mobile)
     
    Meghan O'Donnell
    Global Head, Cardio-Renal-Metabolism Communications and Patient Advocacy
    +41 61 324 9136 (direct)
    +41 79 797 9102 (mobile)
     

    Novartis Investor Relations
    Central investor relations line: +41 61 324 7944
    E-mail:  

    Central   North America  
    Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
    Pierre-Michel Bringer
    Thomas Hungerbuehler 
    Isabella Zinck
    +41 61 324 1065
    +41 61 324 8425
    +41 61 324 7188
    Cory Twining

     
    +1 862 778 3258
           
           

    View Full Article Hide Full Article
  4. Basel, January 6, 2020 Novartis AG (NYSE:NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation ("Purchaser"), for all of the outstanding shares of common stock, par value USD 0.001 per share, of The Medicines Company (NASDAQ:MDCO) (the "Company") at a price of USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding.

    American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised Purchaser that, as of 12:00 midnight, New York City time, at the end of the day on Friday, January 3, 2020 (the "Expiration Time"), the expiration of the tender offer, (i) 60,669,325…

    Basel, January 6, 2020 Novartis AG (NYSE:NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation ("Purchaser"), for all of the outstanding shares of common stock, par value USD 0.001 per share, of The Medicines Company (NASDAQ:MDCO) (the "Company") at a price of USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding.

    American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised Purchaser that, as of 12:00 midnight, New York City time, at the end of the day on Friday, January 3, 2020 (the "Expiration Time"), the expiration of the tender offer, (i) 60,669,325 shares were validly tendered and not withdrawn in the tender offer, representing approximately 75.0% of the outstanding shares of the Company's common stock, and (ii) Notices of Guaranteed Delivery had been delivered with respect to 13,655,837 additional shares, representing approximately 16.9% of the outstanding shares of the Company's common stock.  On January 4, 2020, Purchaser accepted for payment all shares validly tendered and not withdrawn and will promptly pay for such shares.

    Novartis will promptly complete its acquisition of the Company through consummation of a merger of Purchaser with and into the Company, with the Company surviving the merger, without a vote of the Company's stockholders in accordance with Section 251(h) of the Delaware General Corporation Law. Following the merger, the Company will be an indirect wholly-owned subsidiary of Novartis, and each share of the Company's common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Purchaser, the Company, any other subsidiary of Novartis or any subsidiary of the Company, or shares that are held in the Company's treasury, or shares held by any Company stockholder who has properly demanded and perfected appraisal rights under Delaware law) will be converted into the right to receive USD 85.00 per share, net to the seller in cash, without interest and subject to any tax withholding, the same consideration received by stockholders who tendered their shares in the tender offer. As a result of the merger, as of January 6, 2020, the Company common stock will cease to be traded on the NASDAQ Global Select Market.

    Disclaimer
    This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "will," "promptly," "complete," "subject to," "expanding," "growing," "potentially," "first-in-class," "pipeline" or similar terms, or by express or implied discussions regarding the proposed acquisition of the Company by Novartis. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the proposed acquisition described in this press release will be completed, or that it will be completed as currently proposed, or at any particular time.  Neither can there be any guarantee that Novartis or The Medicines Company's product, inclisiran, will achieve any particular future financial results, or that Novartis will be able to realize any of potential strategic benefits, synergies or opportunities as a result of the proposed acquisition.  Nor can there be any guarantee that inclisiran will be submitted or approved for sale in any market, or at any particular time.  Neither can there be any guarantee that such product will be successfully commercialized even if regulatory approvals are obtained. Nor can there be any guarantee that Entresto will be commercially successful in the future. In particular, our expectations could be affected by, among other things:  regulatory actions or delays or government regulation generally, including potential regulatory actions or delays relating to the completion of the potential acquisition described in this release, as well as potential regulatory actions or delays with respect to the development of inclisiran; potential failures to meet remaining closing conditions; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the successful integration of The Medicines Company into the Novartis Group subsequent to the closing of the transaction and the timing of such integration; potential adverse reactions to the proposed transaction by customers, suppliers or strategic partners; dependence on key personnel of The Medicines Company; dependence on third parties to fulfill manufacturing and supply obligations; the uncertainties inherent in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection; safety, quality, data integrity or manufacturing issues; global trends toward health care cost containment, including government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the particular prescribing preferences of physicians and patients; uncertainties regarding actual or potential legal proceedings, including, among others, potential legal proceedings with respect to the proposed acquisition; and other risks and factors referred to in Novartis' current Form 20-F on file with United States Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    About Novartis in Cardiovascular-Renal-Metabolism
    Bending the curve of life requires addressing some of society's biggest public health concerns. Novartis has an established and expanding presence in diseases covering the heart, kidney and metabolic system. In addition to essential treatment Entresto® (sacubitril/valsartan), Novartis has a growing pipeline of potentially first-in-class molecules addressing cardiovascular, metabolic and renal diseases.

    About Novartis
    Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

    Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartisnews
    For Novartis multimedia content, please visit www.novartis.com/news/media-library
    For questions about the site or required registration, please contact 

    # # #

    Novartis Media Relations
    E-mail: 

    Anja von Treskow
    Novartis External Communications
    +41 61 324 2279 (direct)
    +41 79 392 8697 (mobile)


     

    Eric Althoff
    Novartis US Communications
    +1 646 438 4335 (mobile)
    Meghan O'Donnell
    Global Head, Cardio-Renal-Metabolism Communications and Patient Advocacy
    +41 61 324 9136 (direct)
    +41 79 797 9102 (mobile)

    Novartis Investor Relations
    Central investor relations line: +41 61 324 7944
    E-mail: 

    Central   North America  
    Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
    Pierre-Michel Bringer
    Thomas Hungerbuehler 
    Isabella Zinck
    +41 61 324 1065
    +41 61 324 8425
    +41 61 324 7188
    Cory Twining +1 862 778 3258
           
           

     

    View Full Article Hide Full Article
View All Novartis AG News